Surgical results of stage I non-small cell lung cancer: comparison between elderly and younger patients

Yamamoto, Kazumichi; Alarcón, José Padilla; Medina, V. Calvo; García-Zarza, A.; Guillén, J. Pastor; Armengod, E. Blasco; Romeu, F. París

doi:10.1016/s1010-7940(02)00661-9

Cited by 47 publications

(25 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Agarwal, et al [8] also confirmed that the mortality rate increased sharply with age (one year increase of age brought nearly 6% increase in HR) in patients of stage I-II NSCLC. However, some researchers reported that age was not an important prognostic factor for the survival of early stage lung cancer [9] , especially for elderly patients. In addition to facing the threat of cancer-related factors, elderly patients face impacts of complications, organ impairment and other non-cancer related factors.…”

Section: Discussionmentioning

confidence: 99%

Prognostic factors for survival of stage IB upper lobe non-small cell lung cancer patients: A retrospective study in Shanghai, China

Wang

Yang

Wang

2011

Chin. J. Cancer Res.

View full text Add to dashboard Cite

Objective: To identify clinical and pathologic factors that were associated with the survival of stage IB upper lobe non-small cell lung cancer (NSCLC) patients.Methods: A retrospective study of 147 subjects who had undergone curative resection for stage IB upper lobe NSCLC was performed. Patients who had received any adjuvant or neo-adjuvant chemotherapy were excluded. Survival function curves were estimated using the Kaplan-Meier procedure. Crude and adjusted hazard ratios (HRs) of potential prognostic factors were estimated using Cox proportional hazards models.Results: Five factors, including age, tumor size, histologic grade of differentiation, number of removed superior mediastinal lymph node stations and presence of visceral pleura invasion, were significantly and independently associated with mortality risk. Adjusted HRs were 2.6 [95% confidence interval (95% CI): 1.1−6.5] and 4.6 (95% CI: 1.9−11) for those aged 58−68 years and those >68 years, respectively, relative to those aged <58 years. HRs for those with poorly and moderately differentiated tumors were 6.4 (95% CI: 2.3−18) and 1.4 (95% CI: 0.7−2.8), respectively. HRs for those with tumor size 3.1−5 cm and >5 cm (vs ≤3.0 cm) were 2.3 (95% CI: 1.1−4.9) and 4.3 (95% CI: 1.9−10), respectively. The presence of visceral pleura invasion also increased the risk of mortality (HR=4.0, 95% CI: 1.3−12).Conclusion: Advanced age, larger tumor size, poorly differentiated histology, smaller number of removed superior mediastinal lymph node stations, and presence of visceral pleura invasion were associated with poor survival of surgically treated stage IB upper lobe NSCLC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic factors for survival of stage IB upper lobe non-small cell lung cancer patients: A retrospective study in Shanghai, China

Wang

Yang

Wang

2011

Chin. J. Cancer Res.

View full text Add to dashboard Cite

show abstract

“…Nevertheless, all thoracic surgeons carefully assess for comorbid disease as the patient ages, understanding that prolonged anesthesia and the risks involved in intensive care are greater as the patient ages. However, if complete surgical resection of a tumor is possible, then outcome data would suggest that survival is the same as that of a younger patient [9][10][11][12][13][14][15]. Battafarano et al [16] performed a retrospective analysis of 451 patients, looking at the impact of comorbidity on postoperative recovery and long-term survival in patients with stage I NSCLC who underwent complete resections.…”

Section: Surgerymentioning

confidence: 99%

Non-Small Cell Lung Cancer in the Elderly

2004

View full text Add to dashboard Cite

The population is aging both in developing and developed countries. What is clear is that currently over 50% of all patients with non-small cell lung cancer (NSCLC) are 65 years of age or older. When deciding a treatment strategy, the biological rather than the chronological age should be carefully assessed, and treatment should only be modified or withheld for very good reason. This applies equally to surgery, radiation therapy, and chemotherapy. Fortunately, recently published studies have focused on the issue and have provided strong evidence of improved progression-free survival, overall survival, and quality of life in elderly patients with appropriately treated NSCLC. The

show abstract

“…In this population of elderly patients with early-stage NSCLC, the benefit of surgery is well admitted and survival outcomes for patients aged 70 and above are similar to younger patients (18). However, regarding adjuvant chemotherapy, recommendations are still based on retrospective observational data (6).…”

mentioning

confidence: 99%